Company intelligence / Profile preview

Sentinel Software

Houston, Texas, United Statescpl.thalesgroup.com ↗

Ownership: Private
Development stage: Other

Overview

Early clinical data show that localized cytokine immunotherapy can activate effector T cells and upregulate immune checkpoints to enhance checkpoint inhibitor efficacy against difficult-to-treat solid tumors. Safety data were presented at ASCO in June 2025.

Therapeutic areas: Oncology
Modalities: Cell therapyCytokineBiologic
Industry: Biotech

Partnerships

Rice University/Bioengineering lab of Omid Veiseh PhD

Beyond the preview

Go deeper on Sentinel Software.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sentinel Software.

Explore the full profile